Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Industry
 Directory
 Toons & Teasers
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Facilities
 

EquipNet Auction: Lab & Analytical Instruments from Leading Biotech & Pharma Companies - May 24

Check Out Our New Cartoon Celebrating Asian American & Pacific Islander History Month


Utah Life Science Industry Directory

EquipNet Auction: Lab and Analytical Instruments from Leading Biotech and Pharmaceutical Companies - May 24 @ 9 am EST

Banner Advertising

Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and delayed by COVID-19, to be launched in 2022 replacing UtahLifeScience.com. Regrettably, we are working with reduced staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved directory upon the launch of the new site. We apologize for the inconvenience.

Q Therapeutics, Inc.


Q Therapeutics, Inc.
417 Wakara Way, Suite 3510
Salt Lake City, UT 84108
 
 
Phone: (801) 582-5400
Fax: (801) 582-5401
Year Established:  2002
Main Contact: Steven J. Borst, President & CEO
 
Other Contacts:  David A. Green, CPA, CFO
James T. Campanelli, Ph.D., Senior Director, R&D
Mahendra Rao, MD, Ph.D., Co-founder
 
Company Description
Q Therapeutics is engaged in developing adult stem cell therapies to treat debilitating diseases of the central nervous system. The Company’s first product, Q-Cells®, is a cell-based therapeutic intended to restore or preserve normal activity of neurons by providing essential support functions that occur in healthy central nervous system tissues. Q-Cells may be applicable to a wide range of central nervous system diseases, including demyelinating conditions such as multiple sclerosis, transverse myelitis, cerebral palsy and stroke; as well as other neurodegenerative diseases and injuries, such as ALS (Lou Gehrig’s disease), spinal cord injury, Parkinson’s disease and Alzheimer’s disease. Q Therapeutics’ initial clinical target is ALS, with a first IND submission expected in 2013.


Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2022 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

UtahLifeScience.com is owned and published by Info.Resource, Inc.